Shares of health-care companies rose as a move into the riskiest niches of the stock market, including biotech companies, continued. After a precipitous fall ahead of the 2016 presidential election, the iShares Nasdaq Biotech Index exchange-traded fund has now clawed back most of its losses to sit about 15% from its all-time peak.
Continue Reading Below
Ireland-based biotechnology company Shire filed an antitrust suit against rival Allergan, alleging Allergan's contracts with Medicare Part D drug plans for its Restasis eye drops effectively blocked access to Shire's rival dry-eye drug.
-Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
October 02, 2017 16:37 ET (20:37 GMT)